Follow
Sam Y Hong
Title
Cited by
Cited by
Year
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles
V Kumar, SY Hong, AE Maciag, JE Saavedra, DH Adamson, ...
Molecular pharmaceutics 7 (1), 291-298, 2010
982010
Rapamycin-inspired macrocycles with new target specificity
Z Guo, SY Hong, J Wang, S Rehan, W Liu, H Peng, M Das, W Li, S Bhat, ...
Nature chemistry 11 (3), 254-263, 2019
822019
Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis
SA Head, WQ Shi, EJ Yang, BA Nacev, SY Hong, KK Pasunooti, RJ Li, ...
ACS chemical biology 12 (1), 174-182, 2017
742017
“Click” reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donors
OA Oladeinde, SY Hong, RJ Holland, AE Maciag, LK Keefer, JE Saavedra, ...
Organic letters 12 (19), 4256-4259, 2010
322010
Discovery of a potent GLUT inhibitor from a library of rapafucins by using 3D microarrays
Z Guo, Z Cheng, J Wang, W Liu, H Peng, Y Wang, AVS Rao, R Li, X Ying, ...
Angewandte Chemie 131 (48), 17318-17322, 2019
292019
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing …
AE Maciag, RS Nandurdikar, SY Hong, H Chakrapani, B Diwan, ...
Journal of medicinal chemistry 54 (22), 7751-7758, 2011
252011
Anti-tumor effects of Codonopsis lanceolata extracts on human lung and ovarian cancer
YR Cho, SH Kim, HJ Yoon, SY Hong, HY Ko, EH Park, MD Kim, DW Seo
Food Engineering Progress 15 (1), 1-5, 2011
122011
The nitric oxide prodrug V-PROLI/NO inhibits cellular uptake of proline
SY Hong, GL Borchert, AE Maciag, RS Nandurdikar, JE Saavedra, ...
ACS medicinal chemistry letters 1 (8), 386-389, 2010
102010
Glycosylated PROLI/NO derivatives as nitric oxide prodrugs
RS Nandurdikar, AE Maciag, SY Hong, H Chakrapani, ML Citro, ...
Organic letters 12 (1), 56-59, 2010
102010
Improved synthesis of V-PYRRO/NO, a liver-selective nitric oxide prodrug, and analogues
SY Hong, JE Saavedra, LK Keefer, H Chakrapani
Tetrahedron Letters 50 (18), 2069-2071, 2009
82009
Ginsenoside Rp1 inhibits proliferation and migration of human lung cancer cells
SY Hong, JY Cho, DW Seo
Biomolecules & Therapeutics 19 (4), 411-418, 2011
72011
Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1
W Qu, L Cheng, AL Dill, JE Saavedra, SY Hong, LK Keefer, MP Waalkes
Chemico-biological interactions 193 (1), 88-96, 2011
62011
Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1
Y Wang, H Peng, Z Guo, BR Ullman, K Yamamoto, SY Hong, JO Liu
Chemical Science 12 (34), 11484-11489, 2021
42021
An improved synthesis of V-PROLI/NO, a cytochrome P450-activated nitric oxide prodrug
SY Hong, RS Nandurdikar, LK Keefer, JE Saavedra, H Chakrapani
Tetrahedron Letters 50 (31), 4545-4548, 2009
42009
Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
J Liu, J Wang, Z Sun, S Hong
US Patent 10,774,110, 2020
32020
Synthesis and composition of rapafucin libraries
J Liu, J Wang, Z Guo, S Hong, W Liu, H Peng, M Das
US Patent 10,662,220, 2020
22020
Rapafucin derivative compounds and methods of use thereof
J Liu, S Hong, BR Ullman, JE Semple, K Yamamoto, P Kumar, ...
US Patent 11,945,827, 2024
2024
Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
J Liu, J Wang, Z Sun, S Hong
US Patent 11,555,054, 2023
2023
Rapafucin derivative compounds and methods of use thereof
S Hong, BR Ullman, JE Semple, K Yamamoto, P Kumar, M Sadagopan, ...
US Patent App. 17/765,814, 2023
2023
Neuroprotective compounds and methods of use thereof
TM Dawson, VL Dawson, J Liu, H Park, TI Kam, H Peng, VS Ayinampudi, ...
US Patent App. 17/765,418, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20